CBL-514CBL-514

Images are illustrative. Actual specifications are as selected and confirmed in writing.

Dermal & Aesthetic Research

CBL-514

Localized subcutaneous fat reduction

CBL-514 specifications and reference prices. Select a specification to add it to your cart.

5mg/vial x 10vials
Reference priceUS$247.06

For laboratory research only. Not for human or veterinary use.

COA 检测报告 / Reports

Compare all specifications & reference prices
SKUSpecification / packReference price (USD)
CBL-5145mg/vial x 10vialsUS$247.06
CBL-51410mg/vial x 10vialsUS$470.59
CBL-51420mg/vial x 10vialsUS$658.82

Temporarily sold-out specifications can still be added to an inquiry to ask about restocking. An inquiry is not an order or an agreed price.

RESEARCH FOCUS

Main Uses & FAQs

This page organizes directly related data on local subcutaneous fat reduction of CBL-514. First, look at the research questions and findings, then check the population or species, study formulations, and scope of interpretation.

Main TopicsLocalized subcutaneous fat reduction
USAGE REFERENCE

CBL-514 · Usage reference (for research purposes)

The following presents common research-context references for reconstitution, storage, dosage and cycles. The following presents common references in research settings. This page does not constitute advice for use in humans or animals.

🧪Reconstitution

Suggested Diluent
Bacteriostatic Water (containing 0.9% benzyl alcohol); some peptides may use sterile water or acetic acid to aid dissolution. See the individual product descriptions.
Diluent Volume
Slowly introduce the diluent along the vial wall until the lyophilized powder is covered. A common example is 5 mg reconstituted with 2 mL of bacteriostatic water, yielding approximately 2.5 mg/mL. Referenced reconstitution volumes are approximately 1–2.5 mL, with 2 mL commonly used. It is suggested to select and record a fixed volume based on the COA supplied with the purchase.
Handling Notes
Introduce the diluent slowly along the vial wall rather than directly onto the lyophilized powder. Leave it for 60–90 seconds to dissolve naturally; do not shake vigorously.

💾Storage

Unreconstituted Lyophilized Powder
Refrigerate at 2–8°C, protected from light; avoid repeated freeze–thaw cycles.
After Reconstitution
Refrigerate at 2–8°C; a common recommendation is touse within 28 days; do not freeze.
Transport
For short periods, use insulated packaging with ice packs; avoid high temperatures and direct light.

📏Dosage Reference (Research)

Purpose / SettingCommon Reference
ExplanationLocal subcutaneous fat reduction study

🔁Cycle

According to research protocol.

View the Complete Usage Guide Library →

Note: The above describes common research-context references, rather than clinical recommendations. Refer to the batch COA and research protocol. For research use only; not for human or animal use.

Research SummaryKey Findings

What research findings does CBL-514 have regarding the reduction of local subcutaneous fat?

CBL-514 improves doctor/patient ratings and MRI-measured fat volume. Another study reports: reduction in abdominal subcutaneous fat volume; about 69.6% achieved ≥150 mL reduction in 8 weeks.[1] ↗ [2] ↗

Before ReadingStudy populations, species, formulations and delivery conditions each have a defined scope. Research on an ingredient does not establish that this site's product batches have been validated for efficacy in humans or veterinary use.
3 Main ReferencesSorted by First Publication Date ↓
Human Study2026REF. 01

What are the changes in MRI and scoring in phase IIb local fat study?

Research Findings

CBL-514 improves doctor/patient ratings and MRI-measured fat volume.[1] ↗

Study Design

Human random stage IIb; Local abdominal fat

Scope & Limitations

Clinically developed formulation, cannot be equated with research materials on the website.

View the Article Title and Full Citation+

Randomized Phase 2b Trial of CBL-514 Injection for Abdominal Subcutaneous Fat Reduction With Clinician- and Patient-reported Outcomes and MRI Assessment.

Lorenc ZP, Gold M, Schlessinger J, Lain ET, Smith S, Downie J, Cox SE, Ling YF, Sheu AY, Lu CY, Chou YC.

Aesthetic Surgery Journal · Volume and Year 2026
First published 2026-05-20 · PMID 42159040
DOI 10.1093/asj/sjag092

Human Study2025REF. 02

What has been observed in the Abdominal Subcutaneous Fat Randomized Trial?

Research Findings

Decrease in abdominal subcutaneous fat volume; Approximately 69.6% decrease to ≥150 mL after 8 weeks.[2] ↗

Study Design

Human single-blind placebo-controlled randomized Phase II

Scope & Limitations

Short-term local body shaping endpoints, not full-body weight loss.

View the Article Title and Full Citation+

Efficacy and Safety of CBL-514 Injection in Reducing Abdominal Subcutaneous Fat: A Randomized, Single-Blind, Placebo-Controlled Phase II Study.

Gold M, Schlessinger J, Goodman GJ, Dayan S, DuBois J, Ling YF, Sheu AY, Ho WWS, Chou YC.

Aesthetic Surgery Journal · Volume and Year 2025
First published 2025-05-01 · PMID 40037659
DOI 10.1093/asj/sjaf032

Human Study2022REF. 03

What were the findings of early local fat trials of CBL-514?

Research Findings

Specific dosage reduced abdominal fat volume and thickness.[3] ↗

Study Design

Human dose-exploration Phase IIa

Scope & Limitations

2022 early study; dosing density and full bottle specifications cannot be mixed up.

View the Article Title and Full Citation+

Efficacy of a Novel Injection Lipolysis to Induce Targeted Adipocyte Apoptosis: A Randomized, Phase IIa Study of CBL-514 Injection on Abdominal Subcutaneous Fat Reduction.

Goodman GJ, Ho WWS, Chang KJ, Ling YF, Sheu AY.

Aesthetic Surgery Journal · Volume and Year 2022
First published 2022-10-01 · PMID 35709509
DOI 10.1093/asj/sjac162

i

Currently, 3 original studies related to the theme of this page have been selected. The number of studies includes different designs, populations, or preparations, not commercial clinical efficacy ratings. This page is a usage-oriented positive data selection, not a systematic review or dosing recommendation. Historical studies, combination preparations, and special models are all separately indicated.

GO DEEPER

What Questions Do These Studies Address?

Compare study populations, findings and scope.

↗
QUESTIONS, ANSWERED

CBL-514 · Frequently Asked Questions.

What research findings does CBL-514 have regarding the reduction of local subcutaneous fat?+

CBL-514 improves doctor/patient ratings and MRI-measured fat volume. Another study reports: reduction in abdominal subcutaneous fat volume; about 69.6% achieved ≥150 mL reduction in 8 weeks.[1] ↗ [2] ↗

Does CBL-514 reducing local fat equal overall weight loss?+

Not equal. The main studies used abdominal subcutaneous fat volume, thickness, or local scores, addressing local fat reduction, not whole-body weight loss.[1] ↗ [2] ↗ [3] ↗

CBL-514—these conclusions apply to which study populations?+

Human randomization Phase IIb; Local abdominal fat; Human single-blind placebo Randomization Phase II; Human dose exploration Phase IIa. Clinical development formulations cannot be equated with website research materials.[1] ↗ [2] ↗ [3] ↗

VENTRO PEPTIDES & BIOTECH · RESEARCH PRODUCT RETAIL

Research peptides. Shop by product.

Compare specifications, reference prices and COA reports. Add products to your cart to request a quote.

Ventro Peptides & Biotech Logo
QUALITY DOCUMENTSCOA BY PRODUCTGLOBAL DELIVERYTECHNICAL SUPPORT

01 / CATALOG

Browse products

7 products Product names, specifications, and prices follow the current quotation
SemaglutideSM10COA

Images are illustrative. Actual specifications are as selected and confirmed in writing.

GLP-1 & Metabolic Research

Semaglutide

10mg/vial x 10vials

US$90.91
TirzepatideTR20COA

Images are illustrative. Actual specifications are as selected and confirmed in writing.

GLP-1 & Metabolic Research

Tirzepatide

20mg/vial x 10vials

US$160.61
RetatrutideRT10COA

Images are illustrative. Actual specifications are as selected and confirmed in writing.

GLP-1 & Metabolic Research

Retatrutide

10mg/vial x 10vials

US$109.09
BPC157BC10COA

Images are illustrative. Actual specifications are as selected and confirmed in writing.

Repair & Recovery Research

BPC157

10mg/vial x 10vials

US$133.33
MOTS-CMS20COA

Images are illustrative. Actual specifications are as selected and confirmed in writing.

Longevity & Mitochondrial Research

MOTS-C

20mg/vial x 10vials

US$257.58
LiraglutideLR10COA

Images are illustrative. Actual specifications are as selected and confirmed in writing.

GLP-1 & Metabolic Research

Liraglutide

10mg*10vials

US$164.71
IGF-lr3IG1COA

Images are illustrative. Actual specifications are as selected and confirmed in writing.

Growth Hormone & IGF-1

IGF-lr3

1mg/vial x 10vials

US$505.88

03 / ABOUT VENTRO

Reliable peptide supply, built for long-term partnerships.

Ventro supports research product retail purchases with clear pack specifications, available quality documents, and responsive international support.

  • High-purity peptides
  • Available COA reports
  • COA & quality documentation
  • Flexible small-quantity purchases
  • Reliable global fulfillment
  • Research product retail support

04 / QUALITY SYSTEM

Quality without compromise

Browse the available COA reports by product. Confirm documentation for your order with our team.

Controlled quality workflowRaw material to final release
Responsive global supportProduct matching and technical support

RESEARCH PRODUCT INQUIRY

Submit a product inquiry

Tell us the product, specification, and expected quantity. Our team will respond with pricing and available documents.

Use another email app

Opening an inquiry creates a draft, not a sent message. Review and press Send in Gmail, WhatsApp or your email app. Opening a channel passes the draft to the chosen provider. Privacy & cookies

Contact Ventro

Choose a channel to contact the Ventro team directly.

Use another email app

Opening an inquiry creates a draft, not a sent message. Review and press Send in Gmail, WhatsApp or your email app. Opening a channel passes the draft to the chosen provider. Privacy & cookies

WhatsApp